

Rhythm Investor Webinar

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) is pleased to invite shareholders and interested parties to an RHY Investor Briefing and Q&A Session to be held on Wednesday 2nd March 2022 at 9:00 am (AEDT).

The executive management team will be presenting the Company's half year milestones, provide an update on activities focused toward:

- i) the commercialisation of its first product, ColoSTAT®, a simple, low-cost, blood test for global mass market detection of colorectal cancer;
- ii) its platform technology expansion strategy into other cancer targets;
- iii) future catalysts for the current calendar year; and
- iv) a question & answer session with shareholders.

Event details:

Event: Rhythm Biosciences Limited Investor Webinar
Presenters: Otto Buttula, Executive Chairman
Glenn Gilbert, Chief Executive Officer & Managing Director
Time: Wednesday 2nd March 2022, 9:00am (AEDT)
Where: Virtual Webinar, details to be provided upon registration

To register your interest for the webinar please click through to the link below.

Registration Link:

<https://bit.ly/RHY-Call-Mar22>

After registering your interest, you will receive a confirmation email with information on how to join the webinar.

Participants will be able to submit questions via the Panel throughout the presentation, however given we are expecting a large number of attendees we encourage questions to be sent through via email beforehand to ej@irxadvisors.com.

- ENDS -

Authorised for release by the Board.

For further information contact:

Glenn Gilbert
CEO and Managing Director
+61 3 8256 2880

Directors

Otto Buttula
Glenn Gilbert
Trevor Lockett
Rachel David
Louis Panaccio
Eduardo Vom

Executive Chairman
Managing Director
Executive Director
Non-Executive Director
Non-Executive Director
Non-Executive Director

About Rhythm Biosciences

Rhythm Biosciences is focused on becoming a globally significant, transformative, predictive diagnostics company, specialising in cancer detection technology. The Company is currently developing ColoSTAT® - a simple, low-cost, blood test for global mass market detection of colorectal cancer.

Worldwide, colorectal cancer is the third most common cancer in men and the second most common in women, accounting for an estimated 1.9 million new cases and 935,000 deaths annually.

In an effort to reduce the global burden, many countries have implemented screening programs aimed at early detection. These programs are predominantly administered with a faecal immunochemical test (FIT) for the assessment of colorectal cancer risk, with a positive result referred for a colonoscopy. FIT only analyses the presence of blood in faeces, which can occur for several reasons other than cancer, therefore it is not designed as an accurate test for cancer. Many people simply don't take the test for fear of an unnecessary colonoscopy procedure, unpleasantness, difficulty, or for religious/cultural reasons. There is currently no appropriate blood test alternative.

Rhythm aims to transform the global mass-market for colorectal cancer detection with ColoSTAT® its simple, low-cost blood test that is fit for purpose, meaning that it is designed to actually detect colorectal cancer. Since listing on the ASX in 2017, the Company has run a successful multi-year research and development program that has delivered technical validation of the core biomarker technology, being reproducible and stable. The ColoSTAT® test-kit was manufactured in 2021 and delivered performance testing that outperforms the current market standard faecal immunochemical test (FIT) utilising Rhythm's proprietary algorithm. The Company is currently finalising its clinical trial for ColoSTAT®, and is progressing regulatory, manufacturing and scale up activities ahead of market entry in 2022.

ColoSTAT® is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure. ColoSTAT® has the potential to play a key role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer via increasing current screening rates.

Rhythm's initial targeted global addressable population is over 800 million people which are over 50 years of age. Almost 70%, or 550 million people, are not currently screened for colorectal cancer due to the limitations of the current faecal based testing regime. This "at risk" population is also expanding with the disease growing rapidly in much younger age groups. Early detection and intervention can lead to cure in over 90 per cent of new cases, therefore the need for effective screening and early intervention has the potential to save a significant number of lives. Rhythm estimates today's colorectal cancer screening market alone to be worth in excess of \$38 billion.